亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer

医学 阿替唑单抗 肺癌 肿瘤科 临床试验 内科学 无容量 癌症 免疫疗法 外科
作者
Ganessan Kichenadasse,John O. Miners,Arduino A. Mangoni,Andrew Rowland,Ashley M. Hopkins,Michael J. Sorich
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (4): 512-512 被引量:235
标识
DOI:10.1001/jamaoncol.2019.5241
摘要

Importance

High body mass index (BMI) is independently associated with overall survival benefit from immune checkpoint inhibitor therapy in patients with melanoma, yet whether BMI is associated with outcomes in patients with advanced non–small cell lung cancer treated with atezolizumab remains unknown.

Objective

To examine whether BMI is associated with survival outcomes and adverse events in patients with non–small cell lung cancer (NSCLC) treated with atezolizumab.

Design, Setting, and Participants

A pooled analysis of individual patient-level data from 4 international, multicenter clinical trials was performed. Two were single-arm phase 2 trials (BIRCH [data cutoff of May 28, 2015] and FIR [data cutoff of January 7, 2015]), and 2 were 2-arm randomized clinical trials (POPLAR [phase 2; data cutoff of May 8, 2015] and OAK [phase 3; data cutoff of July 7, 2016]). Patients with advanced NSCLC previously untreated or treated with at least 1 line of systemic therapy, with measurable disease and good organ function and without contraindications for chemotherapy or immune checkpoint inhibitor therapy, were included in these trials. Data analyses were performed from February 28, 2019, to September 30, 2019.

Interventions

The control group was treated with docetaxel once every 3 weeks until disease progression or unacceptable toxic effects occurred in POPLAR and OAK. The experimental group was treated with atezolizumab once every 3 weeks until disease progression or unacceptable toxic effects occurred in all available trials.

Main Outcomes and Measures

Association between BMI and overall survival (OS), progression-free survival (PFS), and treatment-related adverse events. Intention-to-treat analysis was conducted.

Results

Adequate data were available for 2110 patients from a total pool of 2261 across 4 trials. Of those 2110, 1434 patients (median age, 64 years [range, 57-70 years]; 890 men [62%]) received atezolizumab and 676 patients (median age, 63 years[range, 57-69 years]; 419 men [62%]) received docetaxel. There was a linear association between increasing BMI and OS in patients treated with atezolizumab. Obesity (BMI ≥30 [calculated as weight in kilograms divided by height in meters squared]) was associated with significantly improved OS in patients treated with atezolizumab, but not in those who received docetaxel after adjusting for confounding variables. The association between BMI and OS/PFS was the strongest in the high PD-L1 expression subgroup. Overall survival for patients with the highest category of PD-L1 expression (≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells; n = 436) had hazard ratios of 0.36 (95% CI, 0.21-0.62) for the group with obesity and 0.69 (95% CI, 0.48-0.98) for the group with overweight. Patients with the highest category of PD-L1 expression had PFS hazard ratios of 0.68 (95% CI, 0.49-0.94) for the group with obesity and 0.72 (95% CI, 0.56-0.92) for the group with overweight. Treatment-related adverse events were not associated with BMI.

Conclusions and Relevance

High BMI appears to be independently associated with improved survival with atezolizumab in patients with NSCLC, raising the possibility that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鸭鸭要学习鸭完成签到 ,获得积分10
25秒前
29秒前
38秒前
啊哒吸哇发布了新的文献求助10
41秒前
Grace完成签到 ,获得积分10
1分钟前
Ava应助陶醉紫青采纳,获得10
1分钟前
1分钟前
在水一方应助WanMoledy采纳,获得10
1分钟前
Jasper应助科研通管家采纳,获得20
1分钟前
愔愔完成签到,获得积分10
2分钟前
时间煮雨我煮鱼完成签到,获得积分10
2分钟前
WanMoledy完成签到,获得积分10
2分钟前
jiajia完成签到 ,获得积分10
2分钟前
2分钟前
许ye完成签到,获得积分10
2分钟前
wanci应助好好采纳,获得10
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
润兴向禧完成签到,获得积分10
3分钟前
小猫多鱼完成签到,获得积分10
3分钟前
3分钟前
3分钟前
好好发布了新的文献求助10
3分钟前
爆米花应助月出西山上采纳,获得10
3分钟前
充电宝应助月军采纳,获得10
3分钟前
未完完成签到 ,获得积分10
3分钟前
寻道图强应助科研通管家采纳,获得50
3分钟前
寻道图强应助科研通管家采纳,获得100
3分钟前
4分钟前
4分钟前
yi完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
5分钟前
5分钟前
5分钟前
SciGPT应助无聊的老六采纳,获得10
5分钟前
陶醉紫青发布了新的文献求助10
5分钟前
高分求助中
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
Evolution 1500
How to Create Beauty: De Lairesse on the Theory and Practice of Making Art 1000
Gerard de Lairesse : an artist between stage and studio 670
Decision Theory 600
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 550
Multiscale Thermo-Hydro-Mechanics of Frozen Soil: Numerical Frameworks and Constitutive Models 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 2989896
求助须知:如何正确求助?哪些是违规求助? 2650511
关于积分的说明 7162877
捐赠科研通 2284921
什么是DOI,文献DOI怎么找? 1211297
版权声明 592507
科研通“疑难数据库(出版商)”最低求助积分说明 591505